Combination Immunotherapy for the Treatment of Cancer

• US 20160244524A1
• Filed: 05/03/2016
• Published: 08/25/2016
• Est. Priority Date: 09/30/2009
• Status: Active Grant

• Current Assignee: Memorial Sloan-Kettering Cancer Center, Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Memorial Sloan-Kettering Cancer Center, Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Allison, James, Sharma, Padmanee, Quezada, Sergio A., Fu, Tihui
• Granted Patent: US 10,023,637 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/74 Inducing cell proliferation
• CPC Class Codes: C07K 2317/75 Agonist effect on antigen
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Claims

1. A method of treating cancer in a patient comprising administering to the patient simultaneously or sequentially a composition comprising a blocking agent to a T cell inhibitory receptor and an agonist to ICOS.

2. The method of claim 1, wherein the blocking agent to a T cell inhibitory receptor is selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody, and a combination thereof.

3. The method of claim 1 or claim 2, wherein the agonist to ICOS is an anti-ICOS antibody.

4. The method of claim 1 or claim 2, wherein the agonist to ICOS is ICOS ligand.

5. The method of claim 4, wherein the ICOS ligand is soluble.

6. The method of claim 4, wherein the ICOS ligand is expressed on the surface of a cell.

7. The method of claim 6, wherein the cell is a tumor cell.

8. The method of claim 7, wherein the tumor cell is irradiated.

9. The method of claim 7, wherein the tumor cell was surgically removed from the patient.